Hosted on MSN
GSK plc (GSK) Stock Rises as FDA Approves Nucala for COPD, CHMP Backs Blenrep for Cancer Treatment
GSK plc (NYSE:GSK) has strengthened its market outlook following major regulatory milestones. The U.S. FDA’s recent approval of Nucala for chronic obstructive pulmonary disease (COPD) and a positive ...
GSK plc has surprised the market with better-than-expected Q1 2026 results, a guidance increase and a maintained dividend, putting the London-based pharma group back in focus for US investors ...
GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified, leading to a "Strong Buy" rating. The company’s diversified portfolio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results